Protara (TARA) Announces Q2 2025 Results; Press Release Furnished

Rhea-AI Filing Summary

On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.

Positive

• Press release furnished publicly announcing quarter-ended June 30, 2025 results, increasing transparency.
• Form 8-K signed by CFO Patrick Fabbio, indicating authorized corporate disclosure.

Negative

• No financial figures or metrics are included in the 8-K text; investors must consult Exhibit 99.1 for actionable data.
• Information is furnished, not filed, so it is not incorporated by reference and carries different legal implications.

Insights

Financial Analyst

Furnished Q2 2025 results announced; 8-K omits figures—investors must read Exhibit 99.1.

The filing is a routine disclosure that notifies the market a press release with quarterly results exists. Because the 8-K body contains no revenue, earnings, or other operating metrics, the market impact depends entirely on the content of Exhibit 99.1. The furnished status limits Exchange Act Section 18 liabilities, so any review of material changes should focus on the press release itself and subsequent filings that might file those figures.

Corporate Governance Expert

Routine compliance filing; exhibits identified and signed by CFO, but substantive data is in the attached press release.

The Form 8-K follows standard practice by furnishing a press release and listing the Interactive Data cover page. Signature by the CFO indicates proper internal authorization. The distinction between furnished and filed is important for legal incorporation; governance and disclosure processes appear observed, but material assessment requires the press release content now attached as Exhibit 99.1.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Protara (TARA) disclose in this Form 8-K?

The company disclosed that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Are the financial results included in the 8-K filing text?

No. The 8-K states the results are provided in the press release attached as Exhibit 99.1; the 8-K body contains no financial figures.

Is the press release in this 8-K considered 'filed' with the SEC?

The filing explicitly states the press release and related information are furnished and shall not be deemed filed under the Exchange Act.

Which exhibits are referenced in the 8-K?

Exhibit 99.1 is the press release dated August 11, 2025, and Exhibit 104 is the Cover Page Interactive Data File.

Who signed the Form 8-K for Protara?

The Form 8-K was signed by Patrick Fabbio, Chief Financial Officer, on August 11, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 08:05 AM Learn about SEC filing dates

false 0001359931 0001359931 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36694		20-4580525
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

345 Park Avenue South Third Floor New York, NY		10010
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 844-0337

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TARA		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2025, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing regardless of any general incorporation language.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 11, 2025, issued by the Registrant.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTARA THERAPEUTICS, INC.
Date: August 11, 2025	By:	/s/ Patrick Fabbio
		Patrick Fabbio
		Chief Financial Officer

2